The One to Beat

Matthew Herper at Forbes lays the credit for the growth of Illumina and next-generation sequencing at the feet of Jay Flatley, the company's chief executive officer. Since 2008, under Flatley's guidance, Illumina's sales have increased nearly 150 percent to $1.42 billion, Herper says, while its stock has shot up some 617 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.